فاس نيوز ميديا جريدة الكترونية جهوية تعنى بشؤون و أخبار جهة فاس مكناس – متجددة على مدار الساعة
A recent study has revealed a significant disparity in drug prices between Morocco and both France and Belgium, with some medications showing shocking price differences reaching up to 1,598% compared to their prices in these European countries.
The study included a comparative analysis of a sample of twenty drugs, most of which are used to treat chronic and serious illnesses. The results showed wide price gaps, particularly in cancer treatment medications.
Among the most striking examples of this price disparity:
- Cancer drug “Temodal 5 mg”:
- Price in Morocco: 219 dirhams
- Price in France: 1.20 euros (equivalent to 12.90 dirhams)
- Difference percentage: over 1,500%
- Other drugs showing similar increases:
- “Eloxatine”
- “Carboplatine Cooper”
- Price differences reached 1,598% in some cases
These findings raise serious questions about:
- Drug pricing mechanisms in Morocco
- Pharmaceutical policies in place
- Effectiveness of price control measures
This substantial price disparity has raised growing concern among patients who bear heavy financial burdens to purchase their necessary medications, especially those with chronic and terminal illnesses.
Observers are calling for a comprehensive review of drug pricing policy in Morocco to ensure the availability of medications at reasonable prices that take into account citizens’ purchasing power, particularly since the current price difference is considered unjustified compared to advanced European countries.
The study’s revelations have sparked a debate about the need for urgent reforms in the pharmaceutical sector to address these significant price disparities and ensure better access to essential medications for Moroccan citizens. This is especially crucial for patients requiring long-term treatment or those fighting serious illnesses, where the cost of medication can represent a significant financial burden.
The findings highlight the importance of implementing more effective price control mechanisms and potentially reviewing existing agreements with pharmaceutical companies to ensure more equitable access to essential medications in Morocco.
